Related Experiment Video
Updated: Apr 17, 2026

Assessing Respiratory Immune Responses to Haemophilus Influenzae
Published on: June 29, 2021
Achromobacter respiratory infections
Colin E Swenson1, Ruxana T Sadikot
11 Division of Pulmonary, Critical Care, and Sleep Medicine, College of Medicine, University of Florida, Gainesville, Florida; and.
Abstract:
Achromobacteria are ubiquitous environmental organisms that may also become opportunistic pathogens in certain conditions, such as cystic fibrosis, hematologic and solid organ malignancies, renal failure, and certain immune deficiencies. Some members of this genus, such as xylosoxidans, cause primarily nosocomially acquired infections affecting multiple organ systems, including the respiratory tract, urinary tract, and, less commonly, the cardiovascular and central nervous systems. Despite an increasing number of published case reports and literature reviews suggesting a global increase in achromobacterial disease, most clinicians remain uncertain of the organism's significance when clinically isolated. Moreover, effective treatment can be challenging due to the organism's inherent and acquired multidrug resistance patterns. We reviewed all published cases to date of non-cystic fibrosis achromobacterial lung infections to better understand the organism's pathogenic potential and drug susceptibilities. We found that the majority of these cases were community acquired, typically presenting as pneumonias (88%), and were most frequent in individuals with hematologic and solid organ malignancies. Our findings also suggest that achromobacterial lung infections are difficult to treat, but respond well to extended-spectrum penicillins and cephalosporins, such as ticarcillin, piperacillin, and cefoperazone.
Insights
Achromobacteria are opportunistic pathogens causing lung infections, often community-acquired pneumonias, particularly in cancer patients. Treatment can be challenging due to multidrug resistance, but extended-spectrum penicillins and cephalosporins show promise.
Area of Science:
- Medical Microbiology
- Infectious Diseases
- Pulmonology
Background:
- Achromobacteria are environmental bacteria with opportunistic pathogenic potential.
- Infections are increasingly reported, yet clinical significance and treatment remain uncertain for many physicians.
- Multidrug resistance complicates effective management of Achromobacteria infections.
Purpose of the Study:
- To review and analyze published cases of non-cystic fibrosis Achromobacteria lung infections.
- To elucidate the pathogenic potential and antimicrobial susceptibility patterns of Achromobacteria in lung infections.
- To provide insights for clinicians managing these challenging infections.
Main Methods:
- Systematic review of all published case reports of non-cystic fibrosis Achromobacteria lung infections.
- Analysis of clinical presentation, patient demographics, and outcomes.
- Evaluation of antimicrobial susceptibility data.
Main Results:
- The majority of reviewed cases were community-acquired pneumonias (88%).
- Hematologic and solid organ malignancies were the most frequent comorbidities.
- Infections were challenging to treat but showed good response to extended-spectrum penicillins and cephalosporins (e.g., ticarcillin, piperacillin, cefoperazone).
Conclusions:
- Achromobacteria are significant causes of community-acquired pneumonia, especially in immunocompromised patients.
- Effective treatment strategies are crucial due to emerging drug resistance.
- Extended-spectrum penicillins and cephalosporins represent viable therapeutic options for Achromobacteria lung infections.
More Related Videos
Related Concept Videos
Microbiota of the Respiratory Tract
Bacterial Phylum Chlamydiae
Atypical Pneumonia
Common Respiratory Disorders
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
Acute Respiratory Failure-III
Bacterial Phylum Actinobacteria

